젬시타빈

용도

• Carcinomas (in combination with carboplatin)
• Exocrine pancreatic carcinoma (Low dose)
• Carcinomas (in combination with carboplatin)
• Bladder urothelial carcinoma, lymphoma, and various carcinomas (High dose)
• Bladder urothelial carcinoma, lymphoma, and various carcinomas (Low dose)
• Carcinomas (Combination therapy)
• Advanced solid tumors

투여 방법

가능한 부작용

• Myelosuppression (neutropenia and thrombocytopenia; nadir at 3-7 days)
• Mild to moderate gastrointestinal toxicity
• Retinal hemorrhage
• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Gastrointestinal toxicity (vomiting, diarrhea, anorexia)
• Retinal haemorrhage
• Treatment-related mortality (due to severe complications)

주의사항 및 금기

• Hypersensitivity to gemcitabine
• Known hypersensitivity to gemcitabine
• Pre-existing bone marrow suppression
• Use with caution in patients with diminished renal or hepatic function. FDA Category D for pregnancy (evidence of fetal risk). Handle with standard cytotoxic safety precautions.

약물 상호작용

• Other myelosuppressive agents: Additive toxic effects (myelosuppression, GI toxicity)

자주 묻는 질문